Alnylam Pharmaceuticals, Inc. has been a registered insider since 2003.
As a Beneficial Owner of 5% or more of a class of the company's shares at Regulus Therapeutics Inc., Alnylam Pharmaceuticals, Inc. last made a transaction on 2/23/2016.
InsiderInsights.com Purchase Scorecard
|
|
|
Transaction Date
|
|
Nq |
Hit
Rate
|
Mean
Return
|
Median
Return
|
Range of
Returns
|
Time From
Purchases
|
Nq |
Hit
Rate
|
Mean
Return
|
Median
Return
|
Range of
Returns
|
| -- |
-- |
-- |
-- |
-- |
1 Year |
-- |
-- |
-- |
-- |
-- |
| -- |
-- |
-- |
-- |
-- |
9 Month |
-- |
-- |
-- |
-- |
-- |
| -- |
-- |
-- |
-- |
-- |
6 Month |
-- |
-- |
-- |
-- |
-- |
| -- |
-- |
-- |
-- |
-- |
3 Month |
-- |
-- |
-- |
-- |
-- |
| -- |
-- |
-- |
-- |
-- |
1 Month |
-- |
-- |
-- |
-- |
-- |
| -- |
-- |
-- |
-- |
-- |
1 Week |
-- |
-- |
-- |
-- |
-- |
InsiderInsights.com Sales Scorecard
|
|
|
Transaction Date
|
|
Nq |
Hit
Rate
|
Mean
Return
|
Median
Return
|
Range of
Returns
|
Time From
Sales
|
Nq |
Hit
Rate
|
Mean
Return
|
Median
Return
|
Range of
Returns
|
| 19 |
16% |
12% |
16% |
140 |
1 Year |
19 |
0% |
-- |
-- |
-- |
| 19 |
11% |
77% |
77% |
230 |
9 Month |
19 |
0% |
-- |
-- |
-- |
| 19 |
5% |
141% |
161% |
262 |
6 Month |
19 |
0% |
-- |
-- |
-- |
| 19 |
26% |
109% |
139% |
238 |
3 Month |
19 |
0% |
-- |
-- |
-- |
| 19 |
37% |
38% |
4% |
268 |
1 Month |
19 |
0% |
-- |
-- |
-- |
| 19 |
37% |
9% |
3% |
173 |
1 Week |
19 |
0% |
-- |
-- |
-- |
| Scorecards Updated 6/13/2023 10:53 PM EST |
Latest Transaction Date: |
2/23/2016 |
| Average days between Transaction and Entered Dates: |
1 |
